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Abstract
Background: Financial incentives have been used for many years internationally to improve quality of care in
general practice. The aim of this pilot study was to determine if offering general practitioners (GP) a small incentive
payment per test would increase chlamydia testing in women aged 16 to 24 years, attending general practice.
Methods: General practice clinics (n = 12) across Victoria, Australia, were cluster randomized to receive either a
$AUD5 payment per chlamydia test or no payment for testing 16 to 24 year old women for chlamydia. Data were
collected on the number of chlamydia tests and patient consultations undertaken by each GP over two time
periods: 12 month pre-trial and 6 month trial period. The impact of the intervention was assessed using a mixed
effects logistic regression model, accommodating for clustering at GP level.
Results: Testing increased from 6.2% (95% CI: 4.2, 8.4) to 8.8% (95% CI: 4.8, 13.0) (p = 0.1) in the control group and
from 11.5% (95% CI: 4.6, 18.5) to 13.4% (95% CI: 9.5, 17.5) (p = 0.4) in the intervention group. Overall, the
intervention did not result in a significant increase in chlamydia testing in general practice. The odds ratio for an
increase in testing in the intervention group compared to the control group was 0.9 (95% CI: 0.6, 1.2). Major
barriers to increased chlamydia testing reported by GPs included a lack of time, difficulty in remembering to offer
testing and a lack of patient awareness around testing.
Conclusions: A small financial incentive alone did not increase chlamydia testing among young women attending
general practice. It is possible small incentive payments in conjunction with reminder and feedback systems may
be effective, as may higher financial incentive payments. Further research is required to determine if financial
incentives can increase testing in Australian general practice, the type and level of financial scheme required and
whether incentives needs to be part of a multi-faceted package.
Trial Registration: Australian New Zealand Clinical Trial Registry ACTRN12608000499381.
Background
Chlamydia trachomatis is the most commonly notified
bacterial sexually transmitted infection (STI) in Austra-
lia, with notification rates rising nearly fourfold over the
past ten years, from 73.5 per 100,000 in 1999 to 273.8
per 100,000 in 2008 [1]. Left untreated, chlamydia can
lead to serious reproductive sequelae including pelvic
inflammatory disease, ectopic pregnancy and infertility
[2,3]. Given that up to 90% of infections are asympto-
matic [3], increased testing is required to effectively
detect and control chlamydia infection and limit its
associated morbidity.
In Australia, national chlamydia testing guidelines
issued by the Royal Australian College of General Prac-
titioners (RACGP) [4] recommend annual testing of
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Australian data show that diagnosis rates are highest
among young women aged under 25 years, who
accounted for just over 40% of all chlamydia notifica-
tions in 2008 [1].
Given that almost 90% of women in this age group
consult a general practitioner (GP) at least once a year
[5], general practice is considered an ideal site through
which to offer chlamydia testing. Currently in Australia
only 12% of women in this age group are tested for
chlamydia each year [6]. Mathematical modelling has
suggested that testing needs to increase to approxi-
mately 30% annually among men and women in this age
group to achieve a significant reduction in prevalence
among women [7].
Previous randomised controlled trials (RCT) have used a
variety of interventions to increase chlamydia testing in
general practice, including educational or continuing med-
ical education interventions [8,9], computerised reminders
[10] and concurrent pap smear and chlamydia testing [11],
however all have had limited success in increasing testing.
In practice, a number of barriers to increased testing exist
for GPs including: a lack of time, insufficient knowledge
about the benefits of testing, discomfort raising the issue
of sexual health in unrelated consultations and difficulty
remembering to offer testing to patients [12-15].
Financial incentives have been used for many years
internationally to improve quality of care in general
practice [16-18]. In the UK, as part of the pilot chlamy-
dia testing program, opportunistic chlamydia testing for
young women increased when general practices were
offered financial incentives for testing [19]. In Australia,
the use of GP financial incentives was first introduced
in 1998 in the form of the General Practice Immunisa-
tion Incentive Scheme (GPII) and successfully increased
childhood immunisation to target rates [5]. The use of
GP financial incentives to increase chlamydia testing in
Australian general practice has been recommended by a
number of researchers in the field [5,10,12,15], however
to date has not been examined.
The aim of this pilot study was to use a RCT design
to determine if offering a $AUD5 payment per chlamy-
dia test to GPs would increase chlamydia testing among
16 to 24 year old women attending general practice.
Methods
Setting
A cluster RCT was undertaken in general practice
clinics in the State of Victoria (population 5.4 million)
[20], Australia, between May 2008 and January 2009.
Eligibility
General practices were eligible to participate if they were
located within Victoria, had a minimum of two full time
equivalent GPs willing to participate and collectively saw
a minimum of 250 women aged 16 to 24 years in the 12
months prior to the trial.
Recruitment methods
General practices were selected from a database collated
from the Victorian ‘Yellow Pages’ telephone directory.
In order to provide adequate representation of general
practices across the state, practices were recruited by
geographical location using the Accessibility Remoteness
Index of Australia (ARIA) [21] and socio-economic sta-
tus using the Socio-Economic Indexes for Areas (SEIFA)
[22]. A total of eight practices were recruited in metro-
politan areas (highly accessible) - two in each SEIFA
quartile - and four in regional/rural areas (accessible/
moderately accessible).
Practices were initially telephoned by a research assis-
tant to invite participation and provide further informa-
tion to interested and eligible clinics. Interested practices
were visited by a research assistant to further outline the
study and obtain consent from GPs. GPs consented to
the collection of de-identified chlamydia testing data and
consultation data on female patients 16 to 24 years old. A
total of 145 practices were approached to recruit 12 prac-
tices into the study. Reasons for non-participation
included a lack of response from GPs (57%), no interest
from GPs (33%), a lack of time (4%), interest shown after
recruitment period had ceased (4%) and clinic participa-
tion in other studies (2%).
Randomisation
The unit of randomisation was the general practice. The
eight metropolitan practices were paired within the four
SEIFA quartiles and one practice in each quartile was
randomised to receive the intervention protocol and the
other the control protocol, using a pre-determined ran-
domisation sequence prepared by the trial statistician.
The statistician was contacted to make the randomised
assignment once two practices had been recruited for
any particular SEIFA quartile. The four regional/rural
practices were also paired - two rural and two regional -
and were assigned within pairs to intervention and con-
trol in the same way as the metropolitan practices. The
allocation was not revealed to staff at either of the
paired practices until representatives from both had
completed the pre-trial requirements (questionnaire,
audit, education session). GPs in the practice were then
contacted by letter to inform them of the allocation
relevant to their practice and reminded of testing pay-
ment or non-payment.
Intervention and control
GPs in both the intervention and control groups were
required to complete a pre-trial questionnaire, a clinical
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ment of the trial. The self-completed pre-trial question-
naire collected information about GPs characteristics,
knowledge, attitudes and practices regarding chlamydia
testing and was conducted both pre and post trial by all
participating GPs. A clinical audit was undertaken at
each practice to collect details about issues likely to
have an impact on chlamydia testing in that clinic.
Audit data were used to develop an ideal individualized
chlamydia testing pathway for each clinic, which incor-
porated current best practice for testing in the primary
care setting of annual chlamydia testing for sexually
a c t i v ew o m e na g e d1 6t o2 4y e a r s[ 2 3 ] .G P sw e r e
advised to collect specimens for testing by first pass
urine, self-collected vaginal swab or endocervical swab.
Participating GPs were eligible to enroll in related chla-
mydia education activities accredited under the RACGP
Quality Assurance and Continuing Professional Devel-
opment Program (QA&CPD) [24].
Following the audit, an education session was held at
each practice to further inform GPs about chlamydia test-
ing, management of test results and methods of introdu-
cing the subject of testing to patients. Practices were
provided with waiting room chlamydia posters, pamphlets
and chlamydia screening flow charts. A DVD recording of
the education session was available for doctors unable to
attend. At the request of GPs, tear off pads with brief
information sheets for patients specifically about the rea-
sons for testing and the simplicity of testing and treatment
were produced and distributed to the practices.
Mid trial, GPs in the intervention group received a let-
ter to remind them of the incentive offered for chlamy-
dia testing. They were not provided with any
information about the number of tests performed to
date nor the amount of money they had accrued
through testing. Payment was made to GPs at the end
of the trial period. All practices received an honorarium
amount of $AUD1000 in recognition of GPs time spent
out of usual roles in participating in the trial.
Outcome measures and data collection
The primary study outcome was the difference in the
proportion of women tested for chlamydia in the control
and intervention groups before and during the interven-
tion. Consultation and chlamydia testing data were col-
lected for two time periods: 12 months prior to and 6
months of the intervention. Data were not collected on
the number, characteristics or identities of women who
were offered or declined testing during the trial.
With the permission of all participating GPs, pathol-
ogy laboratories were provided with each GPs unique
provider number, specific to their place of practice. The
total number of women aged 16 to 24 years tested for
chlamydia at least once in each study time period was
ascertained for each GP as was the total number of
women who had at least one positive chlamydia test
result. Consultation data were collected from each prac-
tice’s computerised patient record system on the num-
ber of individual women aged 16 to 24 years each GP
consulted in the two time periods.
Sample size
At trial commencement, approximately 6% of Australian
women aged 16 to 24 years were being tested each year
for chlamydia by GPs [25]. We hypothesized that the
rate of individual women tested for chlamydia would
rise to 30% in the intervention group (an increase of
24%) and 15% in the control group (change of 9%).
Assuming a conservative intracluster correlation of 0.05
for a cluster size of 100 (which assumes a design effect
of 6), a total of 12 practices (six in each group) would
be required to give 80% power to detect the hypothe-
sized difference with a type 1 error of 5%.
Statistical analysis
In both groups, the proportion of 16 to 24 year old
women tested at least once for chlamydia was estimated
using the observed proportion calculated separately for
the twelve months prior and six months of the trial.
The observed proportion numerator was the number of
women tested at least once for chlamydia and the
denominator, the individual number of women con-
sulted during the time period. The chlamydia positivity
was also calculated and defined as the proportion of
patients tested with at least one positive test. Confidence
intervals for all proportions (using the binomial distribu-
tion) and a p-value for the comparison of estimated pro-
portions between study groups (using the chi-squared
test) separately for the 12 month and 6 month periods
were calculated, adjusted for clustering by GP.
A mixed effects logistic regression model, with two
level hierarchy (patient and individual GP) was fitted to
t h ed a t ai n c l u d i n gr e s u l t sf rom both the intervention
and control group for both time periods. The model
included fixed regression effects for GP age, GP gender,
whether the GP was aware of the RACGP chlamydia
testing guidelines (RACGP ‘Red Book’), whether the GP
had postgraduate qualifications and for an interaction
between the intervention group and the time period.
Statistical analysis was performed using Stata statistical
software 10.0 [26]. Questionnaire data were analyzed
using Statistical Package for the Social Sciences (SPSS)
version 17.0 [27].
Ethical approval
Ethical approval for this study was granted by the
human research ethics committee of The University of
Melbourne (HREC No: 050747).
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This study was registered on the Australian New Zeal-
and Clinical Trial Registry, registration number
ACTRN12608000499381.
Results
Intervention and control groups
A total of 145 practices were approached to participate
i nt h et r i a l-2 6w e r ei n e l i g i b l et op a r t i c i p a t e ,1 0 7
declined and 12 consented to participate (Figure 1). The
first practice was recruited on 12
th May 2008, with the
final practice completing the 6 month trial on the 3
rd
January 2009.
Twenty five GPs in the control group and 20 in the
intervention group consented to the study. During the
trial period, two GPs from one practice (control group)
withdrew.
Table 1 outlines the demographic characteristics of
participating GPs. Groups were comparable with the
exception that control group GPs were more likely to be
younger (under 45 years) and have a post-graduate
qualification.
Proportion of patients tested
In the 12 month pre-trial period, 6.2% (95% CI: 4.2, 8.4)
of women in the control group were tested for
23 practices 
ineligible 
109 practices 
not interested 
Randomisation
Rural 
practices 
N=4
Metropolitan 
practices 
N=8 
12 practices enrolled (45 GPs)  
 [randomly allocated by geographic and 
socio-economic stratum]
144 clinics contacted 
  0 practices  
  2 GPs withdrew  
Control 
6 practices (25 GPs) not offered $5 per 
chlamydia test with 16-24 year olds
0 practices withdrew  
Intervention 
6 practices (20 GPs) offered $5 per 
chlamydia test with 16-24 year olds
Six months later
N=6 practices included 
23 GPs involved 
Six months later
N=6 practices included 
20 GPs involved
Figure 1 Flow of participating practices through the trial. The following figure provides the flow of participating general practices through
the trial.
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the intervention group (Table 2). The median number
of women tested in the control group in the pre-trial
period was 6 (range: 0-29) and in the intervention group
8.5 (range 0-133). At this time, GPs in the intervention
group were more than twice as likely to be testing
w o m e nf o rc h l a m y d i a( O R :2 . 2 ;9 5 %C I :1 . 1 ,4 . 4 ;p=
0.03). During the trial period, there was a non signifi-
cant increase in testing in both the control group, 6.2%
(95% CI: 4.2, 8.4) to 8.8% (95% CI: 4.8, 13.0) (p= 0.1),
and in the intervention group, 11.5% (95% CI: 4.6, 18.5)
to 13.4% (95% CI: 9.5, 17.5) (p = 0.4) (Table 2). The
median number of women tested by GPs in the control
group in the trial period was 5 (range: 0-32) and in the
intervention group 8 (range: 0-49). The proportion of
women who tested positive for chlamydia did not
change in the control group but decreased in the inter-
vention group (p = 0.01) during the two time periods
(Table 2).
The interaction between the estimated effect of time
period and intervention group showed that there was no
difference in the proportion of women tested between
the intervention and control group during the trial (OR
= 0.9; 95% CI: 0.6,1.2) (Table 3).
Barriers and facilitators to testing
The most common barriers to increased chlamydia test-
ing identified in GPs’ post trial questionnaire were: lack
of time (29/43, 69%), difficulty remembering to suggest
testing to patients (9/43, 21.4%) and patients’ lack of
education and awareness about chlamydia testing (9/43,
21.4%). Anecdotally, many GPs noted that while they
initially increased chlamydia testing at the beginning of
the trial, as time progressed, they no longer remembered
to offer testing, and/or forgot about the $5 incentive
payment. The three main facilitators to increased testing
identified by GPs were: financial incentives for GPs (17/
42, 41%), patient education or awareness about testing
(13/42, 31%) and computer prompts or reminders to
test (11/42, 26%).
Discussion
In this study we found that offering GPs a $AUD5 test-
ing payment did not increase testing for chlamydia. This
was the first RCT to test incentive payments for chlamy-
dia testing. Systematic reviews of RCT’s assessing the
effectiveness of financial incentives to improve health
care quality are limited, and often show mixed results
[17,18,28]. Observational studies have found large incen-
tive payments of £10-25 (approximately $AUD20-50)
increased chlamydia testing significantly [19]. Our data
suggest that a small incentive will not substantially
improve chlamydia testing rates.
Strengths and Limitations
The major strength of this study was that it was the first
RCT to our knowledge to examine the effect of provid-
ing GPs with an incentive payment to increase chlamy-
dia testing in general practice. Previous Australian
studies aimed at increasing testing in general practice
have examined the effectiveness of a variety of multi-
faceted and singular method interventions, including the
use of computer alerts [10], concurrent testing with pap
smears [11] and online sexual health assessment tool
referral [12]. Retention rates in the trial were very high,
with a 96% response rate for testing data and question-
n a i r ed a t a .T h es t u d yp r o v i d e dag o o dr e p r e s e n t a t i v e
sample of GPs across regional/rural and metropolitan
Victoria.
Table 1 Demographic characteristics of GPs at trial entry
(n = 43)
#
Characteristic Intervention Control
N (%) (95%CI) N (%) (95%CI)
Number of GPs (N) 20 23
Sex
Male 9 (45) (25,67) 11 (48) (28,68)
Female 11 (55) (33,75) 12 (52) (32,72)
Age
<35 years 3 (15) (5,38) 2 (9) (2,30)
35-44 years 0 (0) (0,17) 9 (39) (21,60)
45-54 years 13 (65) (42,83) 8 (35) (18,56)
55+ years 4 (20) (8,43) 4 (17) (7,39)
Sessions worked each week
<6 sessions 9 (45) (25,67) 7 (30) (15,52)
6-10 sessions 10 (50) (29,71) 16 (70) (48,85)
11+ sessions 1 (5) (0,29) 0 (0) (0,15)
Years in general practice
0-10 years 4 (20) (8,43) 6 (26) (12,48)
11-20 years 6 (30) (14,53) 9 (39) (21,60)
21+ years 10 (50) (29,71) 8 (35) (18,56)
GPs practice location by ARIA
§
Regional/rural 4 (20) (8,43) 5 (22) (9,43)
Metropolitan 16 (80) (57,92) 18 (78) (57,91)
Postgraduate qualifications
No 8 (40) (21,63) 0 (0) (0,15)
Yes 12 (60) (37,79) 23 (100.0) (85,100)
Interest in STIs
Not interested 2 (10) (2,33) 2 (9) (2,30)
Interested 18 (90) (67,98) 21 (91) (70,98)
Aware of RACGP ‘Red Book’^
No 2 (10) (2,33) 2 (9) (2,30)
Yes 5* (23) (10,45) 17 (77) (55,90)
# Adjusted for clustering at GP level
* One missing value
^RACGP ‘Guidelines for preventative activities in general practice 6
th edition’
§ Accessibility Remoteness Index of Australia - indexes of remoteness in
Australia.
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notably, that the observed change in testing was consid-
erably lower than hypothesized. An imbalanced distribu-
tion of variables was also evident at trial
commencement, with GPs in the control group more
likely to be younger and have a postgraduate qualifica-
tion. GPs in the intervention group were also more than
twice as likely to be testing for chlamydia at trial com-
mencement. Although our multivariate analysis did
adjust for these baseline differences, the lower than
hypothesized effect size and the baseline imbalance in
key confounders, did reduce our statistical power. The
comparison of different pre-trial (12 months) and trial
(6 months) time periods may not have allowed for sea-
sonal changes in patient load and possible changes in
testing frequence. In interpreting these results, it is
important to note that one GP in the intervention
group was testing very high numbers of young women
before the trial commenced, accounting for nearly half
the total number of chlamydia tests (44%) in the pre-
trial period, but less than a quarter (23%) in the trial
period. Despite thorough investigation into the decrease
in this GP’s testing figures during the trial period, no
practicable explanation could be found. If this GP is
removed from the multivariate analysis, a greater
increase in testing in the intervention group compared
to the control group is evident suggesting a positive
impact of the incentive payment (from OR = 0.9; 95%
CI: 0.5, 1.6 to OR = 1.22; 95% CI: 0.8, 2.0).
A further limitation of our study is that we did not
provide GPs in the intervention group with ongoing
feedback on their testing performance, nor were incen-
tive payments made until the completion of the trial. It
is likely that GPs forgot they were in the trial and con-
sequently that they would receive payment for each eli-
gible woman tested. The additional use of testing
feedback on the number of tests performed during the
trial period may have been useful in prompting beha-
viour change in GPs [29].
It is likely that testing increased in both groups due to
GPs raised awareness from the educational components
of the study [30-32] - both the intervention and the
control group received the same educational package
prior to commencement in the trial. Educational inter-
ventions as part of a multi-faceted intervention [33], and
which combine strategies such as outreach visits and
printed material have been shown to be effective in
changing physician behaviour [30] without financial
incentive. The significant decrease in positive chlamydia
diagnosis in the intervention group is likely to be as a
result of GPs testing higher numbers of low risk or
asymptomatic women.
Table 2 Pre trial and during trial chlamydia testing numbers, percentages and positivity rates, by control (n = 23) and
intervention (n = 20) groups
Pre-trial period Trial period
Women consulted
N
Women
tested
N (%)
Positive
women
N (%)
Women consulted
N
Women
tested
N (%)
Positive
women
N (%)
Women tested*
P value
Positive women**
P value
Control
16-24 yrs
2689 168 (6.2) 16 (9.5) 1792 157 (8.8) 15 (9.6) p<0.01 p = 0.99
Intervention
16-24 yrs
2662 305 (11.5) 28 (9.2) 1589 213 (13.4) 7 (3.3) p = 0.06 p = 0.01
* The difference in proportion of the number of women tested for chlamydia in the pre-trial and trial periods.
** The difference in proportion of the number of women who tested positive for chlamydia in the pre-trial and trial periods.
Table 3 Adjusted odds ratios (AOR) for the effect of the
intervention on the proportion tested.
Variable AOR
(95%CI)
GP gender Female GPs 1.0
Male GPs 0.6 (0.4, 1.0)
Age group
≤ 44 years 1.0
≥ 45 years 0.5 (0.3, 0.9)
Postgraduate qualifications
No 1.0
Yes 0.7 (0.4, 1.4)
Knowledge of RACGP ‘Red Book’
guidelines
No 1.0
Yes 1.2 (0.7, 2.3)
Study group
Control 1.0
Intervention 2.0 (1.1, 3.5)
Time period
Pre-trial
period
1.0
Trial period 1.5 (1.2, 1.9)
Interaction of time with intervention
Pre-trial
period
1.0
Trial period 0.9 (0.6, 1.2)
# Adjusted for clustering at GP level
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sented in the sample compared with the Australian GP
population and therefore it is possible that the results of
our study may not be generalizable to the wider
population.
While it appears that a small financial incentive did
not motivate behaviour change in GPs, large financial
incentives have shown to be effective in other settings.
In the UK, as part of the 1999/2000 pilot chlamydia
testing program undertaken in two healthcare authori-
ties, financial incentives of up to £25 pounds (approxi-
mately $AUD50) were offered to practices for the
opportunistic chlamydia testing of young women aged
16 to 24 years. General practices comprised a high
proportion of participating health sites (72%), from
which an effective screening rate (ESR) of 46% in the
target female population was achieved in the Ports-
mouth authority, where testing was fully implemented
from the beginning of the program [19]. However,
since the introduction of the National Chlamydia Test-
ing Program (NCSP) in 2003, when financial incentives
were discontinued, the ESR dropped significantly in
general practice to around 10% [34]. Santer et al [35],
in a similar study examining opportunistic chlamydia
testing in primary care among women, reported an
ESR of 30% in women attending for a cervical smear
and 23% for contraception, however conceded it was
unlikely higher rates could be achieved among teenage
women (23%) without the use of a financial incentive
scheme and an education campaign to raise public and
professional awareness [35]. In recent Australian stu-
dies, in which GPs have been asked about how best to
facilitate increased testing in general practice, the need
for financial incentives has been stressed [13,15].
The size of the financial incentive offered in this
study may have been insufficient to motivate GPs to
offer increased testing. Systematic reviews have shown
small financial incentives have mixed results in
improving the quality of physician care [17,18,28].
Town et al [18], in a systematic review of the rando-
mized trials examining the effect of financial incentives
on provider preventative care (n = 8), deduced that
small rewards did not appear to induce change in doc-
tors preventative care practices. A higher incentive
payment or different incentive scheme i.e. target
screening rate bonuses or practice level incentives,
m a yh a v ep r o v e dm o r ee f f e c t i v eh o w e v e r ,ac o s t - e f f e c -
tiveness analysis would need to be undertaken to com-
pare alternative strategies to increase testing [36].
Payments in the UK pilot chlamydia testing program
were considerably higher than those offered here and
were offered to the practice, not the GP, however they
were not sustained as part of the NCSP. In stating this,
there has been evidence to suggest that small incentive
payments to GPs, as part of a multi-faceted package
including regular feedback, have increased childhood
immunization rates in Australia [5].
The lack of reminders may have also have had a nega-
tive impact on the uptake of testing by GPs. Reminders
are generally accepted as an effective way to promote
behaviour change [37,38] and reviews have shown that
computer based alerts can be effective in increasing GPs
preventative care practices [39-41]. In a recent Austra-
lian RCT, in which intervention group GPs received a
computer generated alert to remind them to test young
women for chlamydia, a 27% greater increase in chlamy-
dia testing was evident in the intervention group [10].
The authors concluded that while the computer alert
increased chlamydia testing, the reminder alone would
not be sufficient to increase testing to the levels
required; however, it would be useful as part of a multi-
faceted intervention [10].
Conclusions
Our study suggests that a small financial incentive alone
does not increase chlamydia testing in general practice.
Given the limitations of the study, it is possible that
small incentives with regular feedback or reminders may
increase chlamydia testing in general practice; however
higher financial incentives may also be required. Further
research is required to determine if financial incentives
can increase testing in Australian general practice, the
type and level of financial scheme required and whether
incentives need to be part of a multi-faceted package. A
cost-effective analysis would need to be undertaken to
evaluate the economic viability of alternative incentive
schemes versus other possible interventions to increase
chlamydia testing in general practice.
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